DuPont (formerly DuPont Merck), Neurocrine Biosciences and Cephalon are conducting a joint investigation into corticotropin releasing factor (CRF) ligands. These compounds may have potential as antidepressants and anxiolytics. SV-030 and other analogs from the series are entering preclinical development [361291], [362064].
CRF antagonists DuPont
Preti A.
First
2001-01-01
Abstract
DuPont (formerly DuPont Merck), Neurocrine Biosciences and Cephalon are conducting a joint investigation into corticotropin releasing factor (CRF) ligands. These compounds may have potential as antidepressants and anxiolytics. SV-030 and other analogs from the series are entering preclinical development [361291], [362064].
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
CRFAntagonists.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
65.32 kB
Formato
Adobe PDF
|
65.32 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
